Navigation Links
Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
Date:10/30/2008

SAN FRANCISCO, Oct. 30 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) is pleased to announce the formal establishment of a not-for-profit affiliate, the Canadian Foundation for Global Health (CFGH). CFGH was founded under Canadian Federal Law as a not-for-profit Canadian Corporation headquartered in Ottawa, Ontario, Canada. Under the leadership of Dr. Michael E. Shannon, a founding Director and the foundations' newly appointed President, it is anticipated that the foundation will attract a broad spectrum of the most highly qualified scientists, infectious disease specialists and other medical health professionals from diverse fields of interest to serve on its Board of Directors, Science Advisory Board or as Principal Investigators.

Medizone's Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation's profit follows its' social contribution." The establishment of this foundation fits into that paradigm not only by being positioned to attract the highest quality professionals possible to our research projects, but it is envisioned that as Medizone's products and treatments become ready for market, the foundation may play a vital role as a distribution source for developing countries with varying price breaks depending on the county's needs and the availability of international assistance; we intend to make effort through both the for-profit and the non-profit to make affordable medical solutions as widely available as possible for the people of the planet.

Medizone International, Inc., is a research and development stage company engaged in the development of novel technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to sterilize hospital surgical suites, emergency rooms and intensive care units.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Web site: http://www.medizoneint.com

Investor Relations: 800-953-3350


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
2. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
5. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
6. China Yingxia International, Inc. Appoints New Vice President of Finance
7. Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences
8. Sangui BioTech International, Inc. Files Remaining Reports
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
11. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):